Analyst Expectations For Celldex Therapeutics’s Future
Celldex Therapeutics (NASDAQ:CLDX) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from…
These 3 Real Estate Stocks Delivering High-Dividend Yields Are Recommended By Wall Street’s Most Accurate Analysts
During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors…
Piper Sandler Maintains Underweight On Canopy Growth Stock, Calls Cannabis Rescheduling ‘Largely Symbolic’
A recent company note from Piper Sandler & Co, by senior analysts Michael S.
Critical Insights From Calliditas Therapeutics Analyst Ratings: What You Need To Know
In the last three months, 5 analysts have published ratings on Calliditas Therapeutics (NASDAQ:CALT), offering a diverse range…
Evaluating Realty Income: Insights From 4 Financial Analysts
In the preceding three months, 4 analysts have released ratings for Realty Income (NYSE:O), presenting a wide array…
Ionis Pharmaceuticals Reveals Late-Stage Donidalorsen Data, Analyst Says Results Show Competitive Hereditary Angioedema Profile
Discover the results of Ionis Pharmaceuticals' Phase 3 studies on donidalorsen for hereditary angioedema. FDA application submission expected this year.
Nordstrom Brands Don’t Subscribe To ‘Department Stores Are Dead’ Mantra: Analyst Explains Why
Nordstrom is clearly challenged, with historically choppy gross margins, coupled with Rack's relative underperformance among the off-prices.
AMD, TSMC, Broadcom And Other Chip Stocks Hit By Biden’s Fresh AI Chip Export Restrictions: Details
Embargo on AI chip exports to Middle East triggers selloff in broader sector, including NVDA and AMD. Chip CEOs discuss AI at Taiwan's Computex.
Best Buy To Stabilize Despite A Soft Q1, Analysts Say
Goldman Sachs analyst Kate McShane noted BBY reported better-than-expected Q1 results and provided guidance that still suggests a potential top-line recovery in the second half of the year.
Decoding 6 Analyst Evaluations For CareDx
Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on CareDx (NASDAQ:CDNA)…